EGFR and lung cancer: As MET pathway activation is considered a bona fide bypass resistance pathway in human EGFR-driven lung cancers, murine oncogene-driven lung tumors propagated in immune-competent hosts may represent tractable model systems to explore acquired drug resistance and to define novel combination therapy strategies for prolonging progression free survival.